Bio-Works has confirmed a new order for a customized, prepacked solution worth SEK 0.8 million to be used in a viral vector manufacturing process. The initial order is for process validation runs, and the potential annual revenue from the project is estimated to be between SEK 3-12 million. The customer is an American contract manufacturer of gene therapy products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.68 SEK | -4.96% | -5.96% | -62.25% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-62.25% | 9.64M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.70% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
-0.32% | 24.96B |
- Stock Market
- Equities
- BIOWKS Stock
- News Bio-Works Technologies AB
- Bio-Works Secures SEK 0.8 Million Order for Gene Therapy Manufacturing